Article
Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
Gynecologic oncology - 1 Nov 2024
Škof Erik, Stegel Vida, Dragoš Vita Šetrajčič, Blatnik Ana, Gregorič Brigita, Škerl Petra, Klančar Gašper, Klasinc Anja Zagožen, Bombač Alenka, Krajc Mateja, Novaković Srdjan
Abstract excerpt
OBJECTIVE: In patients with platinum-sensitive relapsed ovarian cancer (PSROC) harboring pathogenic/likely pathogenic variants (PV) in BRCA1 and BRCA2 genes, olaparib maintenance monotherapy (OMT) is a viable option. Our study aimed to evaluate the impact of different BRCA1/2 PV in survival outcomes and safety of OMT in BRCA1/2-mutated PSROC patients, focusing on the type and location of PV. METHODS: We assessed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.